Redeye has updated its estimates and valuation following Physitrack’s Q4 2025 report.
Redeye comments on Fable Media Group’s announcement that founder and majority shareholder Frederik C...
* The reshaping continues... * ...with a potential IPO of the land bank.
Today, trading in Train Alliance shares has been temporarily suspended.
XP Chemistries har tecknat en avsiktsförklaring med en fransk distributör gällande försäljning och ...
Redeye raises its forecasts and Base Case slightly following the acquisition of JOWO, strengthening ...
Redeye comments on ExpreS2ion’s announcement of a planned fully pre-emptive rights issue of approxim...
Redeye positively views the FDA approval of extended labelling for Nevisense, allowing measurements ...
Administer reports Q4 figures on March 4. We expect net sales to have declined slightly in the chall...
Nokian Panimo delivered a solid H2 in line with expectations, entering 2026 with a record product la...
Redeye comments on Enviro’s Q4 report and the company’s application for corporate restructuring, whi...
Redeye gives an initial take on the clinical plan for ELC-401.
Redeye returns with an update following Guldbrev's mixed Q4 report that posted stronger growth than ...
Redeye provides a research update following IRLAB's recent Q4 report, which had no surprises.
Redeye provides its initial take on Heliospectra’s Q4 results, which showed softer-than-expected fig...
As preliminary sales figures were already disclosed, the report did not offer any big surprises.
Physitracks Q4 results aligned with its preliminary figures, highlighted by continued margin expansi...
Nokian Panimo's H2 report was roughly in line with our estimates at the top line and EBITDA level, b...
With key trials successfully initiated and the balance sheet strengthened in 2025, Curasight is set ...
Redeye updates on Better Collective after Q4-results which were slightly above our forecasts while g...
